Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions

被引:162
作者
Broisat, Alexis [1 ,2 ]
Hernot, Sophie [3 ]
Toczek, Jakub [1 ,2 ]
De Vos, Jens [3 ,4 ,5 ]
Riou, Laurent M. [1 ,2 ]
Martin, Sandrine [1 ,2 ,4 ,5 ]
Ahmadi, Mitra [1 ,2 ]
Thielens, Nicole [6 ]
Wernery, Ulrich [7 ]
Caveliers, Vicky [3 ,8 ]
Muyldermans, Serge
Lahoutte, Tony [3 ,8 ]
Fagret, Daniel [1 ,2 ]
Ghezzi, Catherine [1 ,2 ]
Devoogdt, Nick [3 ]
机构
[1] INSERM, U1039, F-38000 Grenoble, France
[2] Univ Grenoble 1, F-38000 Grenoble, France
[3] Vrije Univ Brussel, Vivo Cellular & Mol Imaging Lab, Brussels, Belgium
[4] Vrije Univ Brussel VIB, Dept Biol Struct, B-1050 Brussels, Belgium
[5] Vrije Univ Brussel, Lab Cellular & Mol Immunol, Brussels, Belgium
[6] IBS, CNRS, UMR 5075, Lab Enzymol Mol, Grenoble, France
[7] Cent Vet Res Lab, Dubai, U Arab Emirates
[8] UZ Brussel, Dept Nucl Med, Brussels, Belgium
关键词
atherosclerosis; imaging; nanobody; nuclear medicine; CELL-ADHESION MOLECULE-1; E-SELECTIN; EXPRESSION; PLAQUES; BINDING; MICE; IDENTIFICATION; INFLAMMATION;
D O I
10.1161/CIRCRESAHA.112.265140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies represent potential radiotracers for cardiovascular molecular imaging. Vascular cell adhesion molecule-1 (VCAM1) constitutes a relevant target for molecular imaging of atherosclerotic lesions. Objective: We aimed to generate, radiolabel, and evaluate anti-VCAM1 nanobodies for noninvasive detection of atherosclerotic lesions. Methods and Results: Ten anti-VCAM1 nanobodies were generated, radiolabeled with technetium-99m, and screened in vitro on mouse and human recombinant VCAM1 proteins and endothelial cells and in vivo in apolipoprotein E-deficient (ApoE(-/-)) mice. Anontargeting control nanobody was used in all experiments to demonstrate specificity. All nanobodies displayed nanomolar affinities for murine VCAM1. Flow cytometry analyses using human human umbilical vein endothelial cells indicated murine and human VCAM1 cross-reactivity for 6 of 10 nanobodies. The lead compound cAbVCAM1-5 was cross-reactive for human VCAM1 and exhibited high lesion-to-control (4.95+/-0.85), lesion-to-heart (8.30+/-1.11), and lesion-to-blood ratios (4.32+/-0.48) (P<0.05 versus control C57Bl/6J mice). Aortic arch atherosclerotic lesions of ApoE(-/-) mice were successfully identified by single-photon emission computed tomography imaging. Tc-99m-cAbVCAM1-5 binding specificity was demonstrated by in vivo competition experiments. Autoradiography and immunohistochemistry further confirmed cAbVCAM1-5 uptake in VCAM1-positive lesions. Conclusions: The Tc-99m-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity. Therefore, this study demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. The nanobody technology might evolve into an important research tool for targeted imaging of atherosclerotic lesions and has the potential for fast clinical translation. (Circ Res. 2012;110:927-937.)
引用
收藏
页码:927 / 937
页数:11
相关论文
共 37 条
[1]   Differential Thy-1 expression by splenic fibroblasts defines functionally distinct subsets [J].
Borrello, MA ;
Phipps, RP .
CELLULAR IMMUNOLOGY, 1996, 173 (02) :198-206
[2]   Comprehensive analysis of lymph node stroma-expressed Ig superfamily members reveals redundant and nonredundant roles for ICAM-1, ICAM-2, and VCAM-1 in lymphocyte homing [J].
Boscacci, Remy T. ;
Pfeiffer, Friederike ;
Gollmer, Kathrin ;
Checa Sevilla, Ana Isabel ;
Maria Martin, Ana ;
Soriano, Silvia Fernandez ;
Natale, Daniela ;
Henrickson, Sarah ;
von Andrian, Ulrich H. ;
Fukui, Yoshinori ;
Mellado, Mario ;
Deutsch, Urban ;
Engelhardt, Britta ;
Stein, Jens V. .
BLOOD, 2010, 116 (06) :915-925
[3]   Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p [J].
Broisat, A. ;
Riou, L. M. ;
Ardisson, V. ;
Boturyn, D. ;
Dumy, P. ;
Fagret, D. ;
Ghezzi, C. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (06) :830-840
[4]   Antigen targeted to secondary lymphoid organs via vascular cell adhesion molecule (VCAM) enhances an immune response [J].
Dyer, CM ;
Lew, AM .
VACCINE, 2003, 21 (17-18) :2115-2121
[5]   Atherothrombosis and high-risk plaque Part I: Evolving concepts [J].
Fuster, V ;
Moreno, PR ;
Fayad, ZA ;
Corti, R ;
Badimon, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (06) :937-954
[6]   Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT [J].
Gainkam, Lea Olive Tchouate ;
Huang, Lieven ;
Caveliers, Vicky ;
Keyaerts, Marleen ;
Hernot, Sophie ;
Vaneycken, Ilse ;
Vanhove, Christian ;
Revets, Hilde ;
De Baetselier, Patrick ;
Lahoutte, Tony .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (05) :788-795
[7]   Selection and identification of single domain antibody fragments from camel heavy-chain antibodies [J].
Ghahroudi, MA ;
Desmyter, A ;
Wyns, L ;
Hamers, R ;
Muyldermans, S .
FEBS LETTERS, 1997, 414 (03) :521-526
[8]  
Hernot S, 2011, J CONTROL RELEA 1216
[9]   Adhesion molecules and atherogenesis [J].
Huo, Y ;
Ley, K .
ACTA PHYSIOLOGICA SCANDINAVICA, 2001, 173 (01) :35-43
[10]  
Iiyama K, 1999, CIRC RES, V9, P215